ArticleACS infectious diseases2026
Phenotypic Effects of a Small Molecule CpxA Phosphatase Inhibitor on Uropathogenic Escherichia coli.
Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Patients suffering from Urinary Tract Infections (UTIs) are faced with multidrug resistance and a lack of treatment options. An alternative strategy to traditional bactericidal drug design is to disarm pathogenic bacteria by targeting the regulation of virulence factors. Small-molecule CpxRA phosphatase inhibitor compound 26, hereafter referred to as Cpx26, has shown efficacy in a murine UTI model; however, the impact of pharmacological modulation of CpxRA on bacterial physiology is undefined. Herein, we report the activity of Cpx26 in phenotypic assays to provide insight into its mechanism of action and antivirulence properties. Cpx26 significantly inhibited swimming motility, biofilm formation, and adhesion to bladder epithelial cells at concentrations >60-fold below its MIC. Combination with first-line UTI antibiotics was explored, and synergy was observed with trimethoprim/sulfamethoxazole and fosfomycin, implying potential clinical benefit. This work highlights the potential of antivirulence therapies for prevalent infections such as UTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.